PF-Atlas › Clinical Trials › NCT03450720
Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis
GLPG2737 single dose · Phase 1
Registry ID
NCT03450720
Phase
Phase 1
Status
Completed
Drug / intervention
GLPG2737 single dose
Sponsor
Lakefront Biotherapeutics NV
Start
2017-06-28
Enrollment
6
Locations
1
About this trial
This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03450720 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.